🫀 Semaglutide Improves Glycaemia and Weight in Early Metabolic Abnormalities in Schizophrenia
🔥 Main in 3 points
- Adjunctive semaglutide lowered HbA1c by -0.25% (95% CI, -0.33 to -0.16; P < .001) vs placebo at 26 weeks.
- Mean body weight reduction: -9.2 kg with semaglutide (P < .001); 43% reached low-risk HbA1c (<5.4%) vs 3% on placebo.
- No increase in psychiatric AEs; GI events mild and transient.
🧪 Context
Multicenter, double-blind RCT, 73 adults (mean age 35), schizophrenia spectrum disorders on clozapine/olanzapine with early glycaemic dysregulation, randomized to semaglutide 1 mg SC weekly or placebo for 26 weeks.
📍 Practical significance
Consider early semaglutide in patients with schizophrenia/SGA-induced metabolic risk—even before T2D diagnosis. Monitor usual GI events but psychiatric stability not compromised. Useful to address cardiometabolic risk in this high-vulnerability group.
🔗 Source — PubMed | JAMA Psychiatry
📊 Cardiorenal Outcomes: Semaglutide in T2DM + CKD, Real-World Evidence
🧪 What was studied
Retrospective, propensity-matched US cohort study of overweight/obese adults with T2DM+CKD on semaglutide (n=17,749), tirzepatide (n=4,211), bariatric surgery (n=2,603), vs DPP4i controls; median age ~64; outcomes: ESRD, MI, stroke, all-cause mortality.
📈 Key results
- Semaglutide: HR for ESRD = 0.78; MI = 0.80; stroke = 0.85; all-cause mortality = 0.64 (all significant).
- Tirzepatide: Lower ESRD (HR 0.58), MI, stroke, and mortality also reduced.
- Bariatric surgery: Largest MI, stroke reduction (MI HR 0.45, stroke HR 0.57).
📍 What this changes in practice
Supports semaglutide as disease-modifying therapy for T2DM+CKD—reducing both renal and CV events and mortality, now validated in real world. Bariatric surgery still offers greatest MI/stroke protection, but GLP-1 RA effect is robust and practical in higher-risk/older/less-surgical candidates.
🔗 Source — PubMed | Publisher
✅ Semaglutide and GLP-1 RAs in Reducing Alcohol Use & Related Morbidity: Meta-Analytic Evidence
❓ Practice question
Can semaglutide or GLP-1RA reduce alcohol consumption or risk for alcohol-related harm in clinical settings?
✅ Study answer
- Two robust systematic reviews/meta-analyses (n > 5 million obs.) find:
- Semaglutide/liraglutide reduce Alcohol Use Disorders Identification Test (AUDIT) scores (mean diff -7.8 points, 95% CI -9.02 to -6.60).
- RCTs show semaglutide reduces alcohol craving (p=0.024); real-world data show lower hazard of alcohol-related events with GLP-1RAs (HR 0.64).
- Mechanistic support: reduced cue-reactivity, improved abstinence via weight/metabolic benefits.
📍 How to apply
While current RCT evidence for direct consumption change is mixed/small, consider potential benefit of semaglutide in T2D/obesity patients with comorbid risky alcohol use. Watch for future guideline expansion as more trials report.
🔗 Source
✅ Semaglutide in T1D with Overweight/Obesity: Systematic Review & Meta-Analysis
🧾 Situation
Adults with Type 1 Diabetes, BMI ≥25, overweight/obese, on insulin, seeking better glycaemia/weight control.
✅ Do
- Add GLP-1RA (esp. semaglutide) to insulin: achieved mean weight reduction of -4.3 kg, HbA1c by -0.25%, insulin dose reduced by -9.2 U/day.
- Monitor for GI adverse events (risk increased, mostly mild/moderate).
⚠️ With caution
- Watch for increased hypoglycaemia (OR 1.34), although serious events not higher; adjust insulin dose accordingly.
🔗 Source — PubMed | Diabetes Obes Metab
⚠️ Safety Alert: Semaglutide-Related Worsening of Atypical Anorexia in Adolescents
🧪 Context
Case report: adolescent girl with atypical anorexia prescribed semaglutide "on verge of overweight," presented with severe weight loss, psychiatric deterioration, and repeated hospitalization for eating disorder sequelae.
📊 Numbers
Single case; not generalisable, but illustrates risk. Used semaglutide for 3 months, continued weight loss and restriction after cessation.
📍 Actions
- Avoid semaglutide outside strict obesity or diabetes indications, especially in adolescent/psychiatrically vulnerable populations.
- Screen for eating disorder risk prior to prescription, ensure close psychiatric monitoring.
🔗 Source — PubMed | BJPsych Open
🧠 Semaglutide in T2DM with Obesity & Fatty Liver Disease: Prospective Metabolomics Study
🧪 What was studied
Obese adults with T2DM and MAFLD treated with semaglutide for 12 weeks (n=69); changes in BMI, liver stiffness, insulin resistance and plasma metabolites quantified by mass spec.
📈 Key results
- BMI, liver stiffness, HOMA-IR decreased significantly (all P<0.001).
- Downregulation of long-chain fatty acids, upregulation of carnitines, BCAAs, taurine; shifts in key metabolic pathways (mTOR, unsaturated fatty acid biosynthesis).
- Improvements in glycaemia, lipids, hepatic enzymes, and IL-6.
📍 What this changes in practice
Direct evidence that semaglutide modifies hepatic lipid metabolism and inflammation in MAFLD, congruent with histological/fibrosis improvement data. Reinforces role in T2D+NAFLD/MAFLD.
🔗 Source — PubMed | Zhonghua Nei Ke Za Zhi
🔄 Real-World Weight Outcomes: Bariatric Surgery vs GLP-1RA in U.S. Medicare/Medicaid
🧪 What was studied
Retrospective multicenter cohort: obese T2D adults (n=7667), 7200 on GLP-1RA (semaglutide or tirzepatide), 467 bariatric surgeries. Median age 65 (GLP-1RA) vs 43 (surg). Tracked % weight loss to 3 years.
📈 Key results
- Bariatric surgery: 22.9% total body weight loss at 3 yrs vs 2.3% for any GLP-1RA (p < 0.001).
- 15.9% (surgery) vs 2.4% (GLP-1RA) with ≥12 continuous months Rx.
📍 What this changes in practice
Bariatric surgery remains the most effective long-term weight loss option for eligible patients. GLP-1RA effect in real world is significant but much lower, especially in older, publicly insured groups; consider realistic goal setting and address access/adherence issues.
🔗 Source — PubMed | Surgical Endoscopy
|
